Ivana Bozic
@IBozic_
Followers
519
Following
1K
Media
6
Statuses
456
Associate prof. of applied math @UW. Using math to understand cancer. Branching process fan.
Seattle, WA
Joined September 2020
Thank you @ac_palmer for speaking in the MCMC seminar! The seminar recording is available here:
Excited to announce the second Mathematical and Computational Modeling of Cancer (MCMC) Seminar speaker, Adam Palmer from University of North Carolina, who will be talking on "Modeling tumor heterogeneity to understand the clinical efficacy of combination therapy". 1/3
0
3
10
Reminder of the talk tomorrow! Join us at 9am PDT at
Excited to announce the second Mathematical and Computational Modeling of Cancer (MCMC) Seminar speaker, Adam Palmer from University of North Carolina, who will be talking on "Modeling tumor heterogeneity to understand the clinical efficacy of combination therapy". 1/3
0
3
6
We now also have a seminar website: Many thanks to Rohin Gilman for setting up the website!.
0
1
2
Join us on Tuesday, May 13 at 9am PDT. Seminar will be live streamed on YouTube: 2/3.
1
1
2
Excited to announce the second Mathematical and Computational Modeling of Cancer (MCMC) Seminar speaker, Adam Palmer from University of North Carolina, who will be talking on "Modeling tumor heterogeneity to understand the clinical efficacy of combination therapy". 1/3
1
6
10
Thank you to everyone who joined the seminar today! For those who missed it, you can watch the recording at the same link or by going to the Live tab of the MCMC Seminar page on YouTube.
I am very excited to announce a new online seminar on Mathematical and Computational Modeling of Cancer (MCMC). The first speaker is Robert Noble (City, University of London) on “Understanding, predicting and controlling stochastic cancer evolution”. 1/2
0
1
5
Reminder of the seminar tomorrow - 9am PST (12pm EST, 5pm UK) on Tuesday, March 4. 1/2.
I am very excited to announce a new online seminar on Mathematical and Computational Modeling of Cancer (MCMC). The first speaker is Robert Noble (City, University of London) on “Understanding, predicting and controlling stochastic cancer evolution”. 1/2
2
1
4
Join us on Tuesday, March 4 at 9am PST. The seminar will be streamed live on YouTube:
0
1
4
I am very excited to announce a new online seminar on Mathematical and Computational Modeling of Cancer (MCMC). The first speaker is Robert Noble (City, University of London) on “Understanding, predicting and controlling stochastic cancer evolution”. 1/2
2
9
43
RT @SMB_MathBiology: New #BulletinMathBio paper by Ruibo Zhang and @IBozic_ on Accumulation of Oncogenic Mutations During Progression from….
link.springer.com
Bulletin of Mathematical Biology - Cancers are typically fueled by sequential accumulation of driver mutations in a previously healthy cell. Some of these mutations, such as inactivation of the...
0
5
0
RT @eigensteve: New 20hr bootcamp on Probability & Statistics!!!. Videos released weekly but full playlist already posted:..
0
2K
0
A fascinating story
science.org
Svetlana Mojsov helped discover the hormone GLP-1. Why has she been excluded from its history?
For Svetlana Mojsov, who published key papers on the GLP-1 receptor while at MGH in the 1980s, the Lasker prize caps a mind-bending change of fortune, as she told Science in a Q and A.
0
0
1
RT @FordVersyptLab: Applications are now open for Women in Mathematical Computational Biology collaborative workshop at ICERM in January 20….
0
9
0
RT @uwcherryblossom: Ahem. As the signaler of spring, I officially declare that spring is here! .🌸🌸🌸. #firstdayofspring .
0
82
0
RT @mathoncbro: "Thematic Program on Mathematical Oncology". Fields Inst, July 1 - December 31, 2024. https://t.co/….
0
9
0
Slower clearance may be the simpler explanation, especially as cfDNA is cleared in the liver, and cfDNA concentration is increased the most in the presence of liver cancer. 4/n.
1
0
2
This implies that either the turnover of healthy cells such as leukocytes is increased by the corresponding multiplicative factor, or that clearance of cfDNA is slowed down by the same factor in the presence of early-stage cancer. 3/n.
1
0
1